MedTrace Logo

Prospective Study of FMT for Acute Intestinal GVHD After Allo-HSCT

NCT04711967 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-08-31

No results posted yet for this study

Summary

Acute intestinal GVHD is the main cause of death after allo-HSCT, and FMT is a new treatment method for this disease. In this prospective study, the investigators will recruit intestinal GVHD patients to demonstrate the efficacy and safety of FMT.

Conditions

  • Acute Graft Versus Host Disease in Intestine

Interventions

BIOLOGICAL

Fecal Microbiota Transplantation

fecal microbiota transplantation

DRUG

drug

drug

Sponsors & Collaborators

  • Peking University People's Hospital

    collaborator OTHER

  • Qilu Hospital of Shandong University

    lead OTHER

Principal Investigators

  • Shuqian Xu · Qilu Hospital of Shandong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-10
Primary Completion
2023-07-01
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04711967 on ClinicalTrials.gov